Intramuscular Interferon- -1a: In Patients at High Risk of Developing Clinically Definite Multiple Sclerosis

Author： M. Asif A. Siddiqui   Keri Wellington  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.19, Iss.1, 2005-01, pp. : 55-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treating multiple sclerosis with fingolimod or intramuscular interferon

By Pozzilli Carlo   Prosperini Luca   Borriello Giovanna  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1957-1960

Informa Healthcare

Access to resources Recommend Favorite

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

By Guo Shien   Bozkaya Duygu  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 39-53

Adis International

Access to resources Recommend Favorite

Interferon--1b: Glioma in patients with multiple sclerosis: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1108, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Patients with multiple sclerosis (MS) who receive interferon (IFN)- -1a [`Avonex']

By  

Inpharma, Vol. 1, Iss. 1330, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Patients with multiple sclerosis (MS) who receive interferon (IFN)- -1a [`Avonex']

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 355, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite